BioNeex Interviews

Gene Therapy

Interview with CEO and Founder of Navega Therapeutics, Dr. Ana Moreno

Tue Oct 19 2021 22:35:29 GMT+0000 (Coordinated Universal Time)

Navega Therapeutics is a San Diego based preclinical-stage biotech company developing novel gene therapies for neurological disorders, ophthalmological diseases, and chronic pain.  Retinitis Pigmentosa (RP) is a genetic disease originated by over 200 mutations in more than 50 genes. It is characterized by a loss of rod cells that create a retina degeneration cascade ending up in blindness. The company’s therapeutic candidate is an epigenetic regulator that converts mutation sensitive rod cells to mutation in-sensitive cone cells. The company provided the first demonstration of CRISPR mediated epigenome regulation for engineering in vivo cellular reprogramming and demonstrated direct in vivo cellular reprogramming enabling regenerative medicine.

Tags and Keywords